menu
    • menu
    [{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioDelivery Sciences","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"BioDelivery Sciences \/ BioDelivery Sciences","highestDevelopmentStatusID":"15","companyTruncated":"BioDelivery Sciences \/ BioDelivery Sciences"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"BioDelivery Sciences \/ BioDelivery Sciences","highestDevelopmentStatusID":"15","companyTruncated":"BioDelivery Sciences \/ BioDelivery Sciences"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Collegium Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Ironshore Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0.53000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.55000000000000004,"dosageForm":"Capsule, Extended Release","sponsorNew":"Collegium Pharmaceutical \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Ironshore Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0.55000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.55000000000000004,"dosageForm":"Capsule, Extended Release","sponsorNew":"Collegium Pharmaceutical \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Ironshore Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Collegium Pharmaceutical \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ BioDelivery Sciences","highestDevelopmentStatusID":"11","companyTruncated":"BioDelivery Sciences \/ BioDelivery Sciences"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Alvogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ Alvogen","highestDevelopmentStatusID":"15","companyTruncated":"BioDelivery Sciences \/ Alvogen"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0.59999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.59999999999999998,"dosageForm":"Film, Soluble","sponsorNew":"Collegium Pharmaceutical \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0.59999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.59999999999999998,"dosageForm":"Film, Soluble","sponsorNew":"Collegium Pharmaceutical \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ Endo Pharm","highestDevelopmentStatusID":"15","companyTruncated":"BioDelivery Sciences \/ Endo Pharm"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Tapentadol","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Collegium Pharmaceutical \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Tapentadol","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0.38,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.38,"dosageForm":"Undisclosed","sponsorNew":"Collegium Pharmaceutical \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Collegium Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Collegium Pharmaceutical

    Menu

    Collegium Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Recipient : Ironshore Pharmaceuticals

                            Deal Size : $525.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Collegium Completes Acquisition of Ironshore Therapeutics

                            Details : Collegium will acquire Ironshore, which will help to expand into neurology, which includes JORNAY PM (methylphenidate HCl). It is indicated for the treatment of ADHD in patients 6 years and older.

                            Product Name : Jornay PM

                            Product Type : Miscellaneous

                            Upfront Cash : $525.0 million

                            September 04, 2024

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Recipient : Ironshore Pharmaceuticals

                            Deal Size : $525.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Recipient : Ironshore Pharmaceuticals

                            Deal Size : $550.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

                            Details : Collegium will acquire Ironshore, which will help to expand into neurology, which includes JORNAY PM (methylphenidate HCl). It is indicated for the treatment of ADHD in patients 6 years and older.

                            Product Name : Jornay PM

                            Product Type : Miscellaneous

                            Upfront Cash : $525.0 million

                            July 29, 2024

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Recipient : Ironshore Pharmaceuticals

                            Deal Size : $550.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Recipient : Ironshore Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years with ADHD

                            Details : Methylphenidate HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 28, 2024

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Recipient : Ironshore Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tapentadol

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Collegium Announces Authorized Generic Agreement with Hikma for Nucynta® and Nucynta® ER

                            Details : Through the agreement, Collegium will exclusively manufacture and supply Hikma with all authorized generic products for sale, including Nucynta-Generic (tapentadol HCl).

                            Product Name : Nucynta-Generic

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            April 29, 2024

                            Lead Product(s) : Tapentadol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Celecoxib

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Collegium Announces 11 Poster Presentations at PAINWeek 2022 National Conference

                            Details : ELYXYB™ (celecoxib) oral solution is prescription nonsteroidal anti-inflammatory drug (NSAID) used for the acute treatment of migraine with or without aura in adult.

                            Product Name : Elyxyb

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 30, 2022

                            Lead Product(s) : Celecoxib

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            BioDelivery Sciences

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            BioDelivery Sciences

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buprenorphine

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Recipient : Carolinas Pain Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            True Functional Restoration and Analgesia in Non-Radicular Low Back Pain

                            Details : Buprenorphine is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Low Back Pain.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            June 15, 2022

                            Lead Product(s) : Buprenorphine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Recipient : Carolinas Pain Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buprenorphine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : BioDelivery Sciences

                            Deal Size : $604.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Collegium Completes the Acquisition of BDSI

                            Details : Diversifies and expands Collegium’s revenues by adding BELBUCA® as a second and highly complementary growth driver to Collegium’s highly differentiated pain portfolio, in addition to a contributor with SYMPROIC®, and a new product launch opportunit...

                            Product Name : Belbuca

                            Product Type : Controlled Substance

                            Upfront Cash : $604.0 million

                            March 22, 2022

                            Lead Product(s) : Buprenorphine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : BioDelivery Sciences

                            Deal Size : $604.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Collegium Pharmaceutical

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buprenorphine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : BioDelivery Sciences

                            Deal Size : $604.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio

                            Details : Diversifies and expands Collegium’s revenues by adding BELBUCA as a second and highly complementary growth driver to Collegium’s highly differentiated pain portfolio, in addition to a contributor with Symproic, and a new product launch opportunity wi...

                            Product Name : Belbuca

                            Product Type : Controlled Substance

                            Upfront Cash : $604.0 million

                            February 14, 2022

                            Lead Product(s) : Buprenorphine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : BioDelivery Sciences

                            Deal Size : $604.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            BioDelivery Sciences

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            BioDelivery Sciences

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buprenorphine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Alvogen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Unti...

                            Details : BELBUCA® (buprenorphine) is a medication administered to help manage chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

                            Product Name : Belbuca

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            December 20, 2021

                            Lead Product(s) : Buprenorphine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Alvogen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            BioDelivery Sciences

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            BioDelivery Sciences

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Celecoxib

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            BioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in the U.S....

                            Details : BDSI intends to launch ELYXYB in the first quarter of 2022. Additionally, BDSI plans to conduct an ELYXYB pediatric study, which will have the potential to address the significant unmet needs of pediatric and adolescent patients suffering from migraine a...

                            Product Name : Elyxyb

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 09, 2021

                            Lead Product(s) : Celecoxib

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth